Carl Lokko
- Organon (NYSE:OGN) and partner Shanghai Henlius Biotech said that a phase 3 trial of their biosimilar to Roche’s (OTCQX:RHHBY) Perjuta (pertuzumab) met its primary endpoint.
- That endpoint was the total pathological complete response (tpCR). Secondary endpoints still under evaluation include tpCR rate assessed by investigators; breast
